Report from the Radiation Therapy Committee of the Southwest Oncology Group (SWOG): Research objectives workshop 2008 Journal Article
| Authors: | Okunieff, P.; Kachnic, L. A.; Constine, L. S.; Fuller, C. D.; Gaspar, L. E.; Hayes, D. F.; Hooks, J.; Ling, C.; Meyskens, F. L. Jr; Philip, P. A.; Raben, D.; Smalley, S. R.; Swanson, G. P.; Teicher, B. A.; Thomas, C. R. Jr; Vikram, B.; Zelefsky, M. J.; Baker, L. H. |
| Article Title: | Report from the Radiation Therapy Committee of the Southwest Oncology Group (SWOG): Research objectives workshop 2008 |
| Abstract: | Strategic planning for the Radiation Therapy Committee of the Southwest Oncology Group (SWOG) is comprehensively evaluated every six years in an effort to maintain a current and relevant scientific focus, and to provide a standard platform for future development of protocol concepts. Participants in the 2008 Strategic Planning Workshop included clinical trial experts from multiple specialties, industry representatives from both pharmaceuticals and equipment manufacturers, and basic scientists. High-priority research areas such as image-guided radiation therapy for control of limited metastatic disease, analysis of biomarkers for treatment response and late toxicity, assessment of novel agents in combination with radiation, standardization of radiation target delineation, and the assessment of new imaging techniques to individualize cancer therapy, were discussed. Research priorities included clinical study designs featuring translational end points that identify patients most likely to benefit from combined modality therapy; intervention including combination radiation with standard chemotherapy; radiation with radiosensitizing molecular-targeted therapies; and stereotactic radiation for treatment of patients with regard to asymptomatic metastasis and radiation-induced tumor autoimmunity. The Committee concluded that the future research opportunities are among the most exciting to have developed in the last decade, and work is in progress to embark on these plans. © 2009 American Association for Cancer Research. |
| Keywords: | treatment response; unclassified drug; clinical trial; review; bevacizumab; cisplatin; erlotinib; fluorouracil; cancer combination chemotherapy; nonhuman; antineoplastic agents; clinical trials as topic; gemcitabine; cancer patient; cancer radiotherapy; combined modality therapy; ibritumomab tiuxetan; rituximab; temozolomide; analysis; neoplasms; colorectal cancer; biological marker; carboplatin; biomedical research; ovary cancer; breast cancer; etoposide; lung non small cell cancer; radiotherapy dosage; clinical assessment; cyclophosphamide; diagnostic imaging; oncology; bladder cancer; cancer research; prostate cancer; lung tumor; intervention study; liver metastasis; lung small cell cancer; clinical study; radiation oncology; quality assurance, health care; prostatectomy; lymphoma; vandetanib; mitomycin c; autoimmunity; radiotherapy planning, computer-assisted; taxane derivative; dna topoisomerase inhibitor; navelbine; oxaliplatin; pyrimidine derivative; testis cancer; rectum cancer; radiosensitizing agent; head and neck carcinoma; tirapazamine; vanatinib; translational research |
| Journal Title: | Clinical Cancer Research |
| Volume: | 15 |
| Issue: | 18 |
| ISSN: | 1078-0432 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2009-01-01 |
| Start Page: | 5663 |
| End Page: | 5670 |
| Language: | English |
| DOI: | 10.1158/1078-0432.ccr-09-0357 |
| PUBMED: | 19723641 |
| PROVIDER: | scopus |
| PMCID: | PMC2978526 |
| DOI/URL: | |
| Notes: | --- - "Export Date: 30 November 2010" - "CODEN: CCREF" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work